Nektar Therapeutics (NKTR) EBITDA Margin (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly EBITDA Margin of 359.58% for Q1 2026, up 6618.0% year-over-year from 5.35% in Q1 2025, and down 183.44% quarter-over-quarter from 126.86% in Q4 2025.
Powered by 
Analysis
Nektar Therapeutics (NKTR) EBITDA Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' EBITDA Margin history runs 17 years deep, the most recent figure standing at 359.58% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 6618.0% year-over-year to 359.58%; the TTM figure through Mar 2026 stood at 241.98% (down 11097.0% YoY), while the FY2025 annual figure was 253.66%, down 14678.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 359.58%, down from 126.86% in the prior quarter.
- The five-year high for EBITDA Margin was 49.18% in Q4 2024, with the low at 708.07% in Q2 2022.
- The 5-year median for EBITDA Margin is 238.25% (2022), against an average of 283.32%.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin plunged 31906 bps in 2022, then surged 46123 bps in 2023.
- Nektar Therapeutics' EBITDA Margin stood at 238.25% in 2022, then soared by 41 bps to 140.3% in 2023, then soared by 135 bps to 49.18% in 2024, then slumped by 358 bps to 126.86% in 2025, then tumbled by 183 bps to 359.58% in 2026.
- Business Quant data shows NKTR's EBITDA Margin at 359.58% in Q1 2026, 126.86% in Q4 2025, and 268.63% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn | -417.94% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -417.94% |
| Mar 31, 2026 | -359.58% |
| Dec 31, 2025 | -126.86% |
| Sep 30, 2025 | -268.63% |
| Jun 30, 2025 | -324.21% |
| Mar 31, 2025 | -425.76% |
| Dec 31, 2024 | 49.18% |
| Sep 30, 2024 | -142.37% |
| Jun 30, 2024 | -211.90% |
| Mar 31, 2024 | -163.72% |
| Dec 31, 2023 | -140.30% |
| Sep 30, 2023 | -185.82% |
| Jun 30, 2023 | -246.84% |
| Mar 31, 2023 | -623.83% |
| Dec 31, 2022 | -238.25% |
| Sep 30, 2022 | -229.85% |
| Jun 30, 2022 | -708.07% |
| Mar 31, 2022 | -469.58% |
| Dec 31, 2021 | -451.48% |
| Sep 30, 2021 | -455.82% |